Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

NCT07481786 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma
Brain Metastases
Radiotherapy, Intensity-Modulated
Bevacizumab
Whole-Brain Radiotherapy

Interventions

RADIATION: FSRT
RADIATION: HA-WBRT-SIB
DRUG: Bevacizumab

Sponsor

Sun Yat-sen University